Our Institute under the microscope
Doctoral students and Post Docs
Publications since 2016
Immunology and New Concepts in Immunotherapy
Inserm UMR 1302 / CNRS EMR 6001
The central question of the INCIT joint research unit is to understand the dynamics of the immune response in physiological and pathological situations, in order to highlight the common mechanisms of immune escape in cancer and chronic inflammatory pathologies (inflammation and infection), and to propose original immunotherapy strategies to circumvent these situations.
To achieve this objective, we will rely on tools, cellular and animal models already developed in the unit and those to be developed in the future, as well as on the technological and scientific expertise acquired by the teams over the last 30 years in the knowledge of the various cellular and molecular mediators of innate and adaptive immunity.
To get to know us better, you can also watch this video: https: //youtu.be/tvvd_wqSgmQ
Why a new unit?
Officially created in January 2022, INCIT brings together researchers with over 30 years of experience in immunology and immunotherapy in the region.
Gathering within a human-sized structure avoiding thematic dispersion and administrative heaviness
Focus on immunology
Shared and focused scientific expertise with complementary technologies
Common approaches from basic research to clinical applications
Discover the expertise in Immunology and Immunotherapy in Nantes and Angers
Years of experience
In 1992, publication of the first clinical trial in Europe of adoptive transfer of TILs for the immunotherapy of melanoma.
Scientific organisation of the unit
The scientific organisation of the unit will follow three complementary strategic axes:
The fundamental aspects of our projects aim to identify the pathways/mediators of activation or regulation of the immune response, as well as new targets for the activation or modulation of the immune effectors studied.
- Activation/inhibition pathways of the immune response
- Identification / Characterisation of therapeutic targets
- Characterisation of regulatory mechanisms
- Mechanisms of resistance/response to immunotherapies
Within an "engineering" axis, we will develop tools, protocols and preclinical models, targeting or using the targets, mediators or activation pathways identified in the various basic research programmes.
- Targeting tools
- Optimised T-cells
- Organoids, explants
- Animal models
Our research programmes - most of which are closely linked to clinical transfer - contribute to the development of immunotherapy protocols for the teams with the most advanced projects.
- Selection and amplification of therapeutic T cells
- Transfer transfer of T cells
- Anti-tumour and anti-infective vaccines
- Modulation of inflammatory responses
- Combination therapies
- Tissue repair
Unit projects for 2022-2027
The research programmes aim to understand the fundamental aspects of cellular immunity, both innate and adaptive, as well as the alterations of these responses in severe pathologies, namely certain solid tumours (such as melanoma, colorectal cancer), chronic inflammatory diseases (IBD) and infectious diseases induced by mycobacteria or viruses. In addition to fundamental information, these projects aim to propose innovative immunotherapeutic strategies.
Discover the institute's success stories
Total scientific publications of the 4 Groups
Total clinical publications of the 4 Groups
Biotech start-ups by INCIT members
- Affilogic : Frédéric Pécorari
- Ceeram (acquired by Biomérieux): Jacques Le Pendu
- In-cell-Art : Bruno Pitard
Programmes of excellence
- PIA 2 & 3: LabEx IGO (all INCIT teams)
- RHU: SUccEss (team 2)